GlassScriptPhysician profile
Ernest C Severn
NPI 1326080847
$1,904.26
in general payments reported to CMS, 2019-2025
25 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.69 · 2020: $160 · 2021: $286 · 2022: $320 · 2023: $471 · 2024: $381 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $689.49 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $385.09 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Boston Scientific Corporation | $128.71 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Novo Nordisk INC | $95.40 | 2021-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $56.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $56.67 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Cranial Technologies, INC | $51.98 | 2020-2023 | Doc Band |
| Xeris Pharmaceuticals, INC. | $48.35 | 2024-2025 | Keveyis |
| Organon LLC | $40.16 | 2024-2025 | Nexplanon |
| Pfizer INC. | $38.50 | 2023 | |
| Janssen Pharmaceuticals, INC | $31.89 | 2022-2024 | Xarelto |
| Inspire Medical Systems, INC. | $30.33 | 2024-2025 | Inspire |
| Medtronic, INC. | $29.93 | 2021-2025 | Minimed 780g |
| Lucid Diagnostics INC. | $25.12 | 2022 | |
| Daiichi Sankyo INC. | $24.40 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $23.56 | 2025 | Senza |
| Biogen, INC. | $22.92 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.49 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2019 | |
| Abbott Laboratories | $17.56 | 2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $16.06 | 2022 | |
| Exact Sciences Corporation | $15.38 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $12.56 | 2020 | |
| Shire North American Group INC | $11.61 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Severn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.